U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07458061) titled 'Kamuvudine-9 (K9) in Diabetic Macular Edema' on Feb. 19.
Brief Summary: The objectives of this investigation are to assess:
1. whether oral K9 is safe in subjects with DME, and
2. whether oral K9 improves BCVA compared to oral placebo
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Diabetic Macular Edema
Intervention:
DRUG: Placebo Tablet: BID
Placebo tablets BID
DRUG: Kamuvudine K9
Kamuvudine K9
Recruitment Status: RECRUITING
Sponsor: Dr. Bryan Strelow
Information provided by (Responsible Party): Dr. Bryan Strelow, Vistar Eye Center
Published by HT Digital Content Services with permission from Hea...